MKI67 and prostate carcinoma: However, Dan et al (9), demonstrated that both PI3K inhibitors, LY294002 and ZSTK474, suppress proliferation by decreasing expression of CycD1 and Ki-67, while they do not increase apoptosis in prostate cancer, lung cancer, glioblastoma and colorectal cancer cell lines and in human cancer xenografts.